Ironjustic
Sat, Nov-03-07, 17:16
Go home and die .. or take .. vegetable lecithin .. ? Isn't
that what it says .. ?
"In medicine, describes a disease or condition that does not
respond to treatment."
www.mdanderson.org/patients_public/about_cancer/display.cfm
"80% of phosphatidylcholine recipients discontinued
steroid therapy "
Ann Intern Med. 2007 Nov 6;147(9):603-610. Phosphatidylcholine
for Steroid-Refractory Chronic Ulcerative Colitis: A
Randomized Trial. Stremmel W, Ehehalt R, Autschbach F, Karner
M. University Hospital Heidelberg, Heidelberg, Germany.
BACKGROUND: Although long-term steroid treatment is
discouraged in ulcerative colitis, alternatives are lacking
when therapy with immunosuppressant drugs fails. An
insufficient level of phosphatidylcholine in colonic mucus is
a possible pathogenetic factor for ulcerative colitis.
OBJECTIVE: To see whether steroid withdrawal is easier with
retarded-release phosphatidylcholine or placebo in adults with
chronic steroid- refractory ulcerative colitis. DESIGN:
Randomized, double-blind, placebo-controlled trial conducted
from March 2003 to January 2006. SETTING: University Hospital
Heidelberg, a referral center for inflammatory bowel disease.
PATIENTS: 60 patients with chronic steroid-refractory
ulcerative colitis and high clinical and endoscopic disease
activity indexes (score >/=5). INTERVENTION:
Phosphatidylcholine or cellulose placebo was ingested 4 times
daily for 12 weeks for a total dosage of 2 g/d. The follow-up
rate was 97%. MEASUREMENTS: The number of patients achieving
complete steroid withdrawal and either a low clinical activity
index (</=3) or improvement in the clinical activity index of
50% or more. RESULTS: The primary end point was achieved in 15
of 30 (50%) phosphatidylcholine recipients and in 3 of 30
(10%) placebo recipients (difference, 40% [95% CI, 19% to
61%]; P = 0.002). Twenty-four phosphatidylcholine recipients
(80%) and 3 (10%) placebo recipients discontinued steroid
therapy without disease exacerbation (difference, 70% [CI, 52%
to 88%]; P <0.001). Mild bloating was a common adverse event.
Limitations: The sample size was small, and the study was of
short duration. CONCLUSION: Phosphatidylcholine reduced
corticosteroid dependence more than placebo in patients with
chronic steroid-refractory ulcerative colitis. The next step
is long-term trials to evaluate the sustainability of steroid
withdrawal in these patients. ClinicalTrials.gov registration
number: NCT00259545.
PMID: 17975182 [PubMed - as supplied by publisher]
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
that what it says .. ?
"In medicine, describes a disease or condition that does not
respond to treatment."
www.mdanderson.org/patients_public/about_cancer/display.cfm
"80% of phosphatidylcholine recipients discontinued
steroid therapy "
Ann Intern Med. 2007 Nov 6;147(9):603-610. Phosphatidylcholine
for Steroid-Refractory Chronic Ulcerative Colitis: A
Randomized Trial. Stremmel W, Ehehalt R, Autschbach F, Karner
M. University Hospital Heidelberg, Heidelberg, Germany.
BACKGROUND: Although long-term steroid treatment is
discouraged in ulcerative colitis, alternatives are lacking
when therapy with immunosuppressant drugs fails. An
insufficient level of phosphatidylcholine in colonic mucus is
a possible pathogenetic factor for ulcerative colitis.
OBJECTIVE: To see whether steroid withdrawal is easier with
retarded-release phosphatidylcholine or placebo in adults with
chronic steroid- refractory ulcerative colitis. DESIGN:
Randomized, double-blind, placebo-controlled trial conducted
from March 2003 to January 2006. SETTING: University Hospital
Heidelberg, a referral center for inflammatory bowel disease.
PATIENTS: 60 patients with chronic steroid-refractory
ulcerative colitis and high clinical and endoscopic disease
activity indexes (score >/=5). INTERVENTION:
Phosphatidylcholine or cellulose placebo was ingested 4 times
daily for 12 weeks for a total dosage of 2 g/d. The follow-up
rate was 97%. MEASUREMENTS: The number of patients achieving
complete steroid withdrawal and either a low clinical activity
index (</=3) or improvement in the clinical activity index of
50% or more. RESULTS: The primary end point was achieved in 15
of 30 (50%) phosphatidylcholine recipients and in 3 of 30
(10%) placebo recipients (difference, 40% [95% CI, 19% to
61%]; P = 0.002). Twenty-four phosphatidylcholine recipients
(80%) and 3 (10%) placebo recipients discontinued steroid
therapy without disease exacerbation (difference, 70% [CI, 52%
to 88%]; P <0.001). Mild bloating was a common adverse event.
Limitations: The sample size was small, and the study was of
short duration. CONCLUSION: Phosphatidylcholine reduced
corticosteroid dependence more than placebo in patients with
chronic steroid-refractory ulcerative colitis. The next step
is long-term trials to evaluate the sustainability of steroid
withdrawal in these patients. ClinicalTrials.gov registration
number: NCT00259545.
PMID: 17975182 [PubMed - as supplied by publisher]
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk